This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Daiichi Sankyo Company, Limited. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Takafumi Otsuka: Innovator in Antibody-Drug Conjugates
Introduction
Takafumi Otsuka is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of innovative therapeutic agents.
Latest Patents
Otsuka holds a patent for an "ANTI-EGFR ANTIBODY-DRUG CONJUGATE WITH A CYCLIC DINUCLEOTIDE DERIVATIVE." This invention represents a novel approach to targeted cancer therapy, showcasing his expertise in the intersection of immunology and drug development. He has 1 patent to his name.
Career Highlights
Otsuka is currently employed at Daiichi Sankyo Company, Limited, a leading pharmaceutical company known for its commitment to research and development. His work at Daiichi Sankyo has positioned him at the forefront of innovative drug solutions.
Collaborations
Throughout his career, Otsuka has collaborated with notable colleagues, including Masayuki Ishizaki and Osamu Suzuki. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries.
Conclusion
Takafumi Otsuka's contributions to the field of biotechnology, particularly through his patent on antibody-drug conjugates, highlight his role as an influential inventor. His work continues to impact the development of targeted therapies in cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile